Mariano Santaquilani

TL;DR: This is, to the authors' knowledge, the first worldwide analysis of cancer survival, with standard quality-control procedures and identical analytic methods for all datasets, and should eventually facilitate joint assessment of international trends in incidence, survival, and mortality as indicators of cancer control.

TL;DR: EUROCARE-3 as mentioned in this paper analyzed the survival of 1815584 adult cancer patients diagnosed from 1990 to 1994 in 22 European countries and found that survival was highest in northern Europe (Sweden, Norway, Finland and Iceland), and fairly good in central-southern Europe (France, Switzerland, Austria and Spain).

TL;DR: Survival for most solid cancers, whose prognosis depends largely on stage at diagnosis, was highest in Finland, Sweden, Norway and Iceland, lower in the UK and Denmark, and lowest in the Czech Republic, Poland and Slovenia.

TL;DR: Increases in survival and decreases in geographic differences over time, which are mainly due to improvements in health-care services in countries with poor survival, might indicate better cancer care in wealthy countries with high TNEH.

TL;DR: The EUROCARE-5 survival study estimates survival of children diagnosed with cancer between 2000 and 2007, assesses whether survival differences among European countries have changed, and investigates changes from 1999 to 2007.